FDA Clearance Tracker · P160043-S058
Resolute Onyx Zotarolimus-Eluting Coronary Stent System, Onyx Frontier Zotarolimus-Eluting Coronary Stent System
Last checked: Nov 20, 2026Latest source record: Sep 15, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Sep 15, 2022
Approved
Time to decision
190 days
Received Mar 9, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160043-S058
- Device name
- Resolute Onyx Zotarolimus-Eluting Coronary Stent System, Onyx Frontier Zotarolimus-Eluting Coronary Stent System
- Applicant
- Medtronic Vascular
- Applicant location
- Santa Rosa, CA
- Received
- Mar 9, 2022
- Decided
- Sep 15, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160043
Device type
- Device type
- Coronary drug-eluting stent (NIQ)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the Resolute Onyx and Onyx Frontier Zotarolimus-Eluting Coronary Stent Systems. The device is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus or high bleeding risk, with symptomatic ischemic heart disease due to de novo lesions of length <= 35 mm in native coronary arteries with reference vessel diameters of 2.0 mm to 5.0 mm. In addition, the Resolute Onyx and Onyx Frontier Zotarolimus-Eluting Coronary Stent Systems are indicated for treating de novo chronic total occlusions and non-left main bifurcation lesions utilizing the provisional bifurcation stenting technique.
Source documents
Other decisions for Medtronic Vascular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K232570 · Decided Oct 24, 2023 · 61 days after receipt
Device type: Wire, Guide, Catheter (DQX) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.